NorthWest Biotherapeutics Inc (NWBO)

[f3tt3f]

Not quite the point I was making, but close.

I read that the P3 patients were also randomized by MGMT status, in the trial design pdf that was recently taken down (I'm not sure if this is the only source of the information, if so, please delete this post if it's infringing on private info.)

This means they are well aware of the survival benefit linked to MGMT methylation and have designed the P3 trial with this in mind.
I can't find the MGMT status of the P1 patients, so can't make the assumption that they were aware, or enrolled a patient population heavily weighted to MGMT methylation.
This, along with near-total resection and a younger, healthier, patient set could account for a significant increase in survival over the STUPP OS and PFS figures.

However, I don't think, even in the best case scenario, those beneficial factors could account for the additional survival seen in the P1. (i.e. if there were a control cohort that consisted solely of MGMT methylated patients (with >95% resection, <65 yrs), they would have greater mOS than 18.9 months (most recent benchmark), but not as much as the DCVax arm.
This is, of course, my own conjecture and why I'm invested but the proof will be in the pudding.